The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes

Journal of Immunology

Volumn 178, Issue 7, 2007, Pages 4424-4435

  Alam, S Munir ^a   McAdams, Mildred ^a   Boren, David ^a   Rak, Michael ^a   Scearce, Richard M ^a   Gao, Feng ^a   Camacho, Zenaido T ^a   Gewirth, Daniel ^a,c   Kelsoe, Garnett ^a   Chen, Pojen ^b   Haynes, Barton F ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HAUPTMAN WOODWARD MEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CARDIOLIPIN ANTIBODY; DNA; EPITOPE; GLYCOPROTEIN GP 41; LIPOSOME; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 4E10; NEUTRALIZING ANTIBODY; PHOSPHOLIPID; SYNTHETIC PEPTIDE; VIRUS GLYCOPROTEIN;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; AUTOIMMUNITY; BINDING KINETICS; BINDING SITE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PEPTIDE SYNTHESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TEMPERATURE SENSITIVITY; VIRUS ENVELOPE;

EID: 33947635198     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.7.4424     Document Type: Article

References (56)

1. Ofek, G., M. Tang, A. Sambor, H. Katinger, J. R. Mascola, R. Wyatt, and P. D. Kwong. 2004. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78: 10724-10737.
2. Cardoso, R. M., M. B. Zwick, R. L. Stanfield, R. Kunert, J. M. Binley, H. Katinger, D. R. Burton, and I. A. Wilson. 2005. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22: 163-173.
3. Stiegler, G., R. Kunert, M. Purtscher, S. Wolbank, R. Voglauer, F. Steindl, and H. Katinger. 2001. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 17: 1757-1765.
4. D'Souza, M. P., D. Livnat, J. A. Bradac, and S. H. Bridges. 1997. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group. J. Infect. Dis. 175: 1056-1062.
5. Barbato, G. E., P. Baianchi, P. Inagallinella, W. H. Hurni, M. D. Miller, R. Ciliberto, R. Cortrese, R. Bazzo, J. W. Shiver, and A. Pessi. 2003. Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion. J. Mol. Biol. 330: 1101-1115.
6. Muster, T., F. Steindl, M. Purtscher, A. Trkola, A. Klima, G. Himmler, F. Ruker, and H. Katinger. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol 67: 6642-6647.
7. Zwick, M. B., M. Wang, P. Poignard, G. Steigler, H. Katinger, D. R. Burton, and P. W. Parren. 2001. Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J. Virol. 75: 12198-12208.
8. Zwick, M. B., R. Jensen, S. Church, W. M. G. Stiegler, R. Kunert, H. Katinger, and D. R. Burton. 2005. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J. Virol. 79: 1252-1261.
9. Bures, R., Z. Gaitan, C. Graziosi, K. McGrath, J. Tartaglia, P. Caudrelier, R. El Habib, M. Klein, A. Lazzarin, D. Stablein, et al. 2000. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 16: 2019-2035.
10. Gao, F., E. Weaver, Z. Lu, Y. Li, H.-X. Liao, B. Ma, S. M. Alam, R. Scearce, L. Sutherland, J. Yu, J. Decker, G. Shaw, D. Montefiori, B. Korber, B. Hahn, and B. F. Haynes. 2005. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J. Virol. 79: 1154-1163.
11. Meffre, E., R. Casellas, and M. Nussenzweig. 2000. Antibody regulation of B cell development. Nat. Immunol 1: 379-385.
12. Meffre, E., M. Milili, C. Blanco-Betancourt, H. Antunes, M. C. Nussenzweig, and C. Schiff. 2001. Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development. J. Clin. Invest. 108: 879-886.
13. H amino acid sequences. Int. Immunol. 9: 1503-1515.
14. Schroeder, H. W., Jr., and P. M. Kirkham. 2000. Marriage, divorce, and promiscuity in human B cells. War. Immunol. 1: 187-188.
15. Haynes, B. F., J. Fleming, E. W. St. Clair, H. Katinger, G. Stiegler, R. Kunert, I. Robinson, R. M. Scearce, K. Plonk, H. F. Staats, et al. 2005. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308: 1906-1908.
16. Haynes, B. F., M. A. Moody, L. Verkoczy, G. Kelsoe, and S. M. Alam. 2005. Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum. Antibodies 14: 59-67.
17. Nemazee, D. A., and K. Burki. 1989. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class 1 antibody genes. Nature 337: 562-566.
18. Tiegs, S. L., D. M. Russel, and D. Nemazee. 1993. Receptor editing in self-reactive bone marrow B cells. J. Exp. Med. 177: 1009-1020.
19. Gay, D., T. Saunders, S. Camper, and M. Weigert. 1993. Receptor editing: an approach by autoreactive B cells to escape tolerance. J. Exp. Med. 177: 999-1008.
20. Wardemann, H., S. Yurasov, A. Schaefer, J. W. Young, E. Meffre, and M. C. Nussenzweig. 2003. Predominant autoantibody production by early human B cell precursors. Science 301: 1374-1377.
21. Gharavi, A. E., W. Wilson, and S. Pierangeli. 2003. The molecular basis of antiphospholipid syndrome. Lupus 12: 579-583.
22. Hughes, G. R., N. N. Harris, and A. E. Gharavi. 1986. The anticardiolipin syndrome. J. Rheumatol 13: 486-489.
23. Hunt, J. E., H. P. McNeil, G. J. Morgan, R. M. Crameri, and S. A. Krilis. 1992. A phospholipid-β2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus 1: 75-81.
24. McNally, T., I. J. Mackie, S. J. Machin, and D. A. Isenberg. 1995. Increased levels of β2 glycoprotein-I antigen and β2 glycoprotein-I binding antibodies are associated with a history of thromboembolic complications in patients with SLE and primary antiphospholipid syndrome. Br. J. Rheumatol. 34: 1031-1036.
25. Tsutsumi, A., E. Matsuura, K. Ichikawa, A. Fujisaka, M. Mukai, S. Kobayashi, and T. Koike. 1996. Antibodies to β2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum. 39: 1466-1474.
26. Giles, I., J. D. Haley, I. S. Nagl, D. A. Isenberg, D. Latchman, and A. Rahman. 2003. Systematic analysis of sequences of human antiphospholipid and anti-β2-glycopiotein 1 antibodies: the importance of somatic mutations and certain sequence motifs. Semin. Arthritis Rheum. 32: 246-265.
27. Giles, T., N. Lambrianides, D. Latchman, P. Chen, R. Chukwuocha, D. Isenbeig, and A. Rahman. 2005. The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin. Arthritis Res. Ther. 7: R47-R56.
28. Chukwuocha, R. 2002. Molecular and genetic characterization of five pathogenic and two non-pathogenic monoclonal antiphospholipid antibodies. Mol. Immunol. 39: 299-311.
29. Zhu, M., T. Olee, D. T. Le, R. A. Roubey, B. H. Hahn, V. L. Woods, Jr., and P. P. Chen. 1999. Characterization of IgG monoclonal anti-cardiolipin/anti- β2GP1 antibodies from two patients with antiphospholipid syndrome reveals three species of antibodies. Br. J. Haematol. 105: 102-109.
30. Wyatt, R., J. Moore, M. Accola, E. Desjardin, J. Robinson, and J. Sodroski. 1995. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J. Virol. 69: 5723-5733.
31. Wyatt, R., P. D. Kwong, E. Desjardins, R. W. Sweet, J. Robinson, W. A. Hendrickson, and J. Sodroski. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393: 705-711.
32. Liao, H.-X., L. Sutherland, S.-M. Xia, M. Brock, R. Scearce, S. Vanleeuwen, S. M. Alam, M. McAdams, E. Weaver, Z. T. Camacho, et al. 2006. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 353: 268-282.
33. Scearce, R. M., and G. S. Eisenbarth. 1983. Production of monoclonal antibodies reacting with the cytoplasm and surface of differentiated cells. Methods Enzymol. 103: 459-469.
34. Earl, P. L., C. C. Broder, D. Long, S. A. Lee, J. Peterson, S. Chakrabarrti, R. W. Doms, and B. Moss. 1994. Native oligomeric human immunodeficiency virus type I envelope glycoproteins elicits diverse monoclonal antibody reactivities. J. Virol. 68: 3015-3026.
35. Alam, S. M., C. A. Paleos, H.-X. Liao, R. Scearce, R. Robinson, and B. F. Haynes. 2004. An inducible HIV type I gp41 HR-2 peptide-binding site on HIV type I envelope gp120. AIDS Res. Hum. Retroviruses 20: 836-845.
36. Janeway, C. A., P. Travers, M. Walport, and M. Schlomchik. 2005. The recognition of antigen. In Immunobiology: The Immune System in Health and Disease, 6th Ed. Garland Science, Taylor and Francis Group, New York and London, pp. 103-130.
37. Ways, J. P., and P. Parham. 1983. The binding of monoclonal antibodies to cell-surface molecules. Biochem. J. 216: 423-432.
38. MacKenzie, C. R., T. Hirama, S. Deng, D. Bundle, S. Narang, and N. M. Young. 1996. Analysis by surface plasmon resonance of the influence of valence on the ligand binding affinity and kinetics of an anti-carbohydrate antibody. J. Biol. Chem. 271: 1527-1533.
39. Rahman, A. 2004. Autoantibodies, lupus and the science of sabotage. Rheumatology 43: 1326-1336.
40. H-CDR3 and specificity for native DNA among autoimmune antibodies. J. Immunol. 157: 2430-2439.
41. Klasse, P. J., and J. Blomberg. 1987. Patterns of antibodies to human immunodeficiency virus proteins in different subclasses of IgG. J. Infect. Dis. 156: 1026-1030.
42. Loder, F., B. Mutschler, R. J. Ray, C. J. Paige, P. Sideras, R. Torres, M. C. Lamers, and R. Carsetti. 1999. B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. J. Exp. Med. 190: 75-89.
43. Sims, G. P., R. Ettinger, Y. Shirota, C. H. Yarboro, G. G. Illei, and P. E. Lipsky. 2005. Identification and characterization of circulating human transitional B cells. Blood 105: 4390-4398.
44. McCaughey, G. B., M. Citron, R. Danzeisen, R. Freidinger, V. M. Garsky, W. M. Hurni, J. Joyce, X. Liang, M. Miller, M. Shiver, and M. J. Bogusky. 2003. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 mAb. Biochemistry 42: 3214-3223.
45. Grundner, C., T. Mirazabekov, J. Sodroski, and R. Wyatt. 2002. Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins. J. Virol. 76: 3511-3521.
46. Zhang, W., A. P. Godillot, R. Wyatt, J. Sodroski, and I. Chaiken. 2001. Antibody 17b binding at the coreceptor site weakens the kinetics of the interaction of envelope glycoprotein gp120 with CD4. Biochemistry 40: 1662-1670.
47. Lipschultz, C. A., Y. Li, and S. J. Smith-Gill. 2000. Experimental design for analysis of complex kinetics using surface plasmon resonance. Methods 20: 310-318.
48. Lipschultz, C. A., A. Yee, S. Mohan, Y. Li, and S. J. Smith-Gill. 2002. Temperature differentially affects encounter and docking thermodynamics of antibody-antigen association. J. Mol. Recog. 15: 44-52.
49. Boffey, J., D. Nicholl, E. R. Wagner, K. Townson, C. Goodyear, K. Furkawa, J. Conner, and H. J. Willison. 2004. Innate murine B cells produce anti-disialosyl antibodies reactive with Campylobacter jejuni LPS and gangliosides that are polyreactive and encoded by a restricted set of unmutated V genes. J. Neuroimmunol. 152: 98-111.
50. Vila, P., M. C. Hernandez, M. F. Lopez-Fernandez, and J. Batlle. 1994. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb. Haemost. 72: 209-213.
51. Trkola, A., H. Kuster, P. Rusert, B. Joos, M. Fischer, C. Leemann, A. Manrique, M. Huber, M. Rehr, A. Oxenius, et al. 2005. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11: 615-622.
52. Markowitz, M. 2006. Monoclonal antibody infusions delay HIV-1 rebound after discontinuation of ARV therapy. In 13th Conference on Retroviruses and Opportunistic Infections 2006, February 5-8, Denver, CO, Abstract 178.
53. Joos, B., A. Trkola, H. Kuster, L. Aceto, M. Fischer, G. Steigler, C. Ambruster, B. Vcelar, H. Katinger, and H. F. Gunthard. 2006. Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (mAbs) against human immunodeficiency virus type 1 envelope gp120 (mAb 2G12) and gp41 (mAbs 4E10 and 2F5). Antimicrob. Agents Chemother. 50: 1773-1779.
54. Zhu, P., J. Liu, J. Bess, E. Chertova, J. Lifson, H. Grise, G. Ofek, K. Taylor, and K. H. Roux. 2006. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441: 847-852.
55. Sanchez-Martinez, S., M. Lorizate, H. Katinger, R. Kunert, G. Basanez, and J. L. Nieya. 2006. Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody. FEBS Lett. 580: 2395-2399.
56. Brunel, F., M. B. Zwick, R. Cardoso, J. Nelson, I. Wilson, D. Burton, and P. E. Dawson. 2006. Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type I antibody. J. Virol. 80: 1680-1787.